GlassScriptPhysician profile
Douglas A Crase
NPI 1295115236
$2,164.14
in general payments reported to CMS, 2019-2025
25 companies · $548 in 2025
The $548 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.97 · 2020: $54.39 · 2021: $14.61 · 2022: $158 · 2023: $658 · 2024: $660 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,866.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $518.02 | 2019-2025 | Airsupra, Breztri, Bevespi Aerosphere |
| Lilly USA, LLC | $362.34 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $243.33 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $133.50 | 2022-2024 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $117.72 | 2023-2025 | Freestyle Libre |
| Pfizer INC. | $110.09 | 2019-2025 | |
| Daiichi Sankyo INC. | $94.45 | 2022-2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $76.36 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.69 | 2022-2023 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $60.13 | 2022-2023 | Rexulti, Abilify Maintena |
| Merck Sharp & Dohme LLC | $53.96 | 2020-2025 | Capvaxive, Vaxneuvance, Gardasil 9 |
| Lundbeck LLC | $51.19 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $35.16 | 2023-2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $31.24 | 2023 | Eliquis |
| Abbvie INC. | $30.12 | 2023 | Vraylar |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $30.06 | 2021-2025 | Jada System |
| Pharmacosmos Therapeutics INC. | $27.83 | 2025 | Monoferric |
| Biohaven Pharmaceutical Holding Company LTD. | $20.86 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.17 | 2025 | Caplyta |
| Gilead Sciences, INC. | $16.93 | 2024 | |
| Mylan Specialty L.P. | $16.89 | 2024 | Yupelri |
| Dexcom, INC. | $15.56 | 2024 | Dexcom G6 Transmitter |
| Viatris Specialty LLC | $14.02 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $13.53 | 2024 | Austedo Xr |
| Sumitomo Pharma America, INC. | $3.99 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Crase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.